Evidence map›Paper›PMID 32968068›Full record

ArticleNature communications2020

Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.

Stephen T Magill, Harish N Vasudevan, Kyounghee Seo, Javier E Villanueva-Meyer, Abrar Choudhury, S John Liu, Melike Pekmezci, Sarah Findakly, Stephanie Hilz, Sydney Lastella and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 5 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Stephen T Magill *Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-5257-7835
Harish N Vasudevan *Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Kyounghee SeoDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, 94143, USA.
Abrar ChoudhuryDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0001-8312-2457
S John LiuDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0003-1042-0191
Melike PekmezciDepartment of Pathology, University of California San Francisco, San Francisco, CA, 94143, USA.
Sarah FindaklyDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Stephanie HilzDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Sydney LastellaDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Benjamin DemareeDepartment of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California San Francisco, San Francisco, CA, 94143, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Manish K AghiDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Philip V TheodosopoulosDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Adam R AbateDepartment of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California San Francisco, San Francisco, CA, 94143, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Michael W McDermottDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Daniel A LimDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Erik M UllianDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, 94143, USA.
Joseph F CostelloDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
David R RaleighDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA. david.raleigh@ucsf.edu.ORCID http://orcid.org/0000-0001-9299-8864
University of California, San Francisco · USQB3 · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
Understanding How Ciliary Hedgehog Signaling Causes MedulloblastomaK08CA212279 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2017 to 2021
$886k
Developing astrocyte, neuron, and microglial 3D organoids to model key aspects of human pathologyR03AG063157 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 2019 to 2021
$333k
Investigating the Regulation and Role of FOXM1 in Aggressive MeningiomaF30CA246808 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOUDHURY, ABRAR · 2020 to 2023
$159k
Development of a molecular diagnostic and prognostic signature for meningiomaF32CA213944 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAGILL, STEPHEN T · 2017 to 2017
$63k
NCI NIH HHS F30 CA246808NCI NIH HHS F32 CA213944NCI NIH HHS K08 CA212279NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA227136NIA NIH HHS R03 AG063157NIGMS NIH HHS T32 GM007618NINDS NIH HHS R01 NS079697
6 · The paper itself

Abstract

Meningiomas are the most common primary intracranial tumors, but the molecular drivers of meningioma tumorigenesis are poorly understood. We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate biologic drivers and reveal new targets for molecular therapy. To test this hypothesis, here we perform multiplatform molecular profiling of 86 spatially-distinct samples from 13 human meningiomas. Our data reveal that regional alterations in chromosome structure underlie clonal transcriptomic, epigenomic, and histopathologic signatures in meningioma. Stereotactic co-registration of sample coordinates to preoperative magnetic resonance images further suggest that high apparent diffusion coefficient (ADC) distinguishes meningioma regions with proliferating cells enriched for developmental gene expression programs. To understand the function of these genes in meningioma, we develop a human cerebral organoid model of meningioma and validate the high ADC marker genes CDH2 and PTPRZ1 as potential targets for meningioma therapy using live imaging, single cell RNA sequencing, CRISPR interference, and pharmacology.

Indexed as

Genetic HeterogeneityAgedAntigens, CDBrain NeoplasmsCadherinsDiffusion Magnetic Resonance ImagingEpigenomicsFemaleGene Expression ProfilingGenetic MarkersGenomicsHumansMagnetic Resonance ImagingMeningeal NeoplasmsReceptor-Like Protein Tyrosine Phosphatases, Class 5TranscriptomeAntigens, CDCadherinsCDH2 protein, humanGenetic MarkersPTPRZ1 protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 5

Identifiers

PMID32968068
PMCPMC7511976
OpenAlexW3089289983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.